Proenzyme therapy of cancer

Anticancer Research

Volumn 25, Issue 2 A, 2005, Pages 1157-1177

  Novak, Josef F ^a   Trnka, Frantisek ^b  

^a BUCKNELL UNIVERSITY   (United States)

^b Biology Bldg 204 ^*  (Czech Republic)

Author keywords

Cancer; Proenzyme therapy; Protease inhibitors

Indexed keywords

AMYLASE; ANGIOSTATIN; CHYMOTRYPSIN; CHYMOTRYPSINOGEN; ENDOSTATIN; ENZYME PRECURSOR; PANCREAS ENZYME; TRYPSIN; TRYPSINOGEN;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER THERAPY; CELL COMMUNICATION; CELL MOTILITY; CELL SHAPE; CELL STRUCTURE; CELL TYPE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSKELETON; DRUG ACTIVITY; DRUG ISOLATION; DRUG MECHANISM; DRUG PURIFICATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME THERAPY; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; METASTASIS INHIBITION; MONOLAYER CULTURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; TUMOR CELL; TUMOR GROWTH;

ADHERENS JUNCTIONS; AMYLASES; ANGIOSTATINS; ANIMALS; CATTLE; CELL COUNT; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; CHYMOTRYPSIN; CHYMOTRYPSINOGEN; DOGS; ENDOSTATINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICROFILAMENTS; NEOPLASMS; RATS; SPHEROIDS, CELLULAR; TIGHT JUNCTIONS; TRYPSIN; TRYPSINOGEN;

EID: 17444368071     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (129)

1. Beard J: The cancer problem. The Lancet 168: 281-283, 1905.
2. Cleaves MA: Pancreatic ferments in the treatment of cancer and their role in prophylaxis. Med Record 70: 918-919, 1906.
3. Rice CC: Treatment of cancer of the larynx by subcutaneous injection of pancreatic extract (trypsin). A case of growth, supposed to be carcinoma, cured. Med Record 70: 812-816, 1906.
4. Wiggin FH: Case of multiple fibrosarcoma of the tongue, with remarks on the use of trypsin and amylopsin in the treatment of malignant disease. JAMA 47: 2003-2008, 1906.
5. Golley FB: Two cases of cancer treated by the injection of pancreatic extract. Med Record 70: 918-919, 1906.
6. Scott CC: Case Report. The General Practitioner, pp.803-805, 1907.
7. Campbell JT: Trypsin treatment of a case of malignant disease, involving the left tonsil, base of tongue and epiglottis. JAMA 48: 225-226, 1907.
8. Goeth RA: Pancreatic treatment of cancer, with report of a cure. JAMA 48: 1030, 1907.
9. Dupuy H: Favorable effect of trypsin in a case of laryngeal epithelioma: exhibition of a case. New Orleans Med Surg J 59: 911-915, 1907.
10. Cutfield A: Trypsin treatment of malignant disease. BMJ 2: 525, 1907.
11. Donati M: Contributo alla cura dei tumori maligni mediante iniezioni di tripsina. La Riforma Medica 23: 225-229, 1907.
12. Marsden A: Carcinoma of cervix uteri successfully treated with the pancreatic ferments. The General Practitioner, January 11, 22-23, 1908.
13. Golley FB: Two cases of cancer treated with trypsin. Med Record 75: 804-805, 1909.
14. Lambelle FW: A further report of the case of pensioner W. Du T., late drummer, No. 5669, permanent staff, 4th battalion West Yorkshire Regiment; reprinted in Beard [15], (pp. 209-210).
15. Beard J: The Enzyme Treatment of Cancer and its Scientific Basis. London , Chatto and Windus, 1911.
16. Hald PT: Comparative researches on the tryptic strength of different trypsin preparations and on their action on the human body. The Lancet 2: 1371-1375, 1907.
17. Bainbridge WS: The Enzyme Treatment for Cancer. Committee on Scientific Research, New York Skin and Cancer Hospital; pp. 39, 1909.
18. Shimkin MB: Contrary to the Nature. Washington, D.C., U.S. Department of Health, Education, and Welfare, Public Health Service, National Institutes, 1977.
19. Rather LJ: The Genesis of Cancer. A Study in the History of Ideas. Baltimore, The Johns Hopkins University Press, 1978.
20. Olson JS: The History of Cancer. An Annotated Bibliography. Greenwood Press, New York, 1989.
21. Weiss L: Metastasis of cancer: a conceptual history from antiquity to the 1990s. Cancer Metast Rev 19: 193-385, 2000.
22. Mossner J, Secknus R, Meyer J, Niederau C and Adler G: Treatment of pain with pancreatic extracts in chronic pancreatitis: results of a prospective placebo-controlled multicenter trial. Digestion 53: 54-66, 1992.
23. Goldberg DM: Enzymes as agents for the treatment of disease. Clin Chim Acta 206: 45-76, 1992.
24. Layer P and Keller J: Pancreatic enzymes: secretion and luminal nutrient digestion in health and disease. J Clin Gastroenterol 28: 3-10, 1999.
25. Dale PS, Tamhankar CP, George D and Daftary GV: Co-medication with hydrolytic enzymes in radiation therapy of uterine cervix: evidence of the reduction of acute side effects. Cancer Chemother Pharmacol 47(Suppl): S29-S34, 2001.
26. Billigmann P: Enzyme therapy - an alternative in treatment of herpes zoster. Adv Med 39: 44-48, 1995.
27. Targoni OS, Tary-Lehmann M and Lehman PV: Prevention of murine EAE by oral hydrolytic enzyme. J Autoimmunity 12: 191-198 1999.
28. Beuth J, Ost B, Pakdaman A, Rethfeldt E, Bock PR, Hanisch J and Schneider B: Impact of complementary oral enzyme application on the postoperative treatment results of breast cancer patients - results of an epidemiological multicentre retrolective cohort study. Cancer Chemother Pharmacol 47(Suppl.): 845-854, 2001.
29. Popiela T, Kulig J, Hanisch J and Bock PR: Influence of a complementary treatment with oral enzymes on patients with colorectal cancers - an epidemiological retrolective cohort study. Cancer Chemother Pharmacol 47(Suppl.): S55-S63, 2001.
30. Sakalova A, Bock PR, Dedik L, Hanisch J, Schiess W, Gazova S, Chabronova I, Holomanova D, Mistrik M and Hrubisko M: Retrolective cohort study of an additive therapy with an oral enzyme preparation in patients with multiple myeloma. Cancer Chemother Pharmacol 47(Suppl): S38-S44, 2001.
31. Desser L, Sakalova A, Zavadova E, Holomanova D and Mohr T: Oral enzyme therapy improves remission time, soluble TNF-receptors and β2-microglobulin concentration in chemotherapy treated multiple myeloma patients. Int J Tissue React 19: 94, 1997.
32. Zavadova E, Desser L and Mohr T: Stimulation of reactive oxygen species production and cytotoxicity in human neutrophils in vitro and after oral administration of a polyenzyme preparation. Cancer Biother 10: 147-152, 1995.
33. Gujral MS, Patnaik PM, Kaul R, Parikh HK, Conradt C, Tamhankar CP and Daftary GV: Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers. Cancer Chemother Pharmacol 47(Suppl.): S23-S28, 2001.
34. Streichhan P, van Schaik W and Stauder G: Bioavailability of therapeutically used hydrolytic enzymes. In: Absorption of Orally Administered Enzymes. (Gardner MLG and Steffens K-J, eds). Berlin, Springer Verlag, pp. 83-94, 1995.
35. Gewert K, Holowachuk SA, Rippe C, Gregory PC, Erlanson-Albertsson C, Olivecrona G, Kruszewska D, Piedra JV, Westrom B and Pierzynnowski SG: The enzyme levels in blood are not affected by oral administration of a pancreatic enzyme preparation (Creon 10,000) in pancreas-insufficient pigs. Pancreas 28: 80-88, 2004.
36. Ziv E, Lior O and Kidron M: Absorption of protein via the intestinal wall. A quantitative model. Bioch Pharmacol 36: 1035-1039, 1987.
37. Gotze H and Rothman SS: Enteropancreatic circulation of digestive enzyme as a conservation mechanism. Nature 257: 607-609, 1975.
38. Rothman S, Liebow C and Isenman L: Conservation of digestive enzymes. Physiol Rev 82: 1-18, 2002.
39. Carrell RW and Boswell DR: Serpins: the superfamily of plasma serine proteinase inhibitors. In: Proteinase Inhibitors (Barrett AJ and Salvesen G, eds). Amsterdam, Elsevier Science Publishers BV, pp. 403-420, 1986.
40. Bode W and Huber R: Natural protein proteinase inhibitors and their interaction with proteinases. Eur J Biochem 204: 433-451, 1992.
41. Borgstrom A, Erlanson-Albertsson C and Borgstrom B: Human pancreatic proenzymes are activated at different rates in vitro. Scand J Gastroenterol 28: 455-459, 1993.
42. Trnka F, Rybak M, Marek R and Vavra L: Pharmaceutical composition containing an isolated protease proenzyme, amylase, and aprotinin. United States Patent # 5, 858, 357, 1999.
43. Folkman J and Hochberg M: Self-regulation of growth in three dimensions. J Exp Med 138: 745-753, 1973.
44. Yuhas JM, Li AP, Martinez AO and Landman AJ: A simplified method for production and growth of multicellular tumor spheroids. Cancer Res 37: 3639-3743, 1977.
45. Reijerkerk A, Voest EE and Gebbink MFBG: No grip, no growth: the conceptual basis of excessive proteolysis in the treatment of cancer. Eur J Cancer 36: 1695-1705, 2000.
46. Scorilas A, Karameris A, Arnogiannaki N, Ardavanis A, Bassilopoulos P, Trangas T and Talieri M: Overexpression of metalloproteinase-9 in human breast cancer: a potential favorable indicator in node-negative patients. Br J Cancer 84: 1488-1496, 2001.
47. Yu H, Levesque MA, Clark GM and Diamandis EP: Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. Clin Cancer Res 4: 1489-97, 1998.
48. Faff O, Mitreiter R, Muckter H, Ben-Shaul Y and Bacher A: Rapid formation of tight junctions in HT 29 human adenocarcinoma cells by hypertonic salt solutions. Exptl Cell Res 177: 60-72, 1988.
49. Fidler IJ and Nicolson G: Organ selectivity for implantation, survival and growth of B16 variant tumor lines. J Natl Cancer Inst 57: 1199-1202, 1976.
50. Roblin R, Chou I-N and Black PH: Proteolytic enzymes, cell surface changes, and viral transformation. Adv Cancer Res 22: 203-260, 1975.
51. Fidler IJ: Critical factors in the biology of human cancer metastasis. Cancer Res 50: 6130-6138, 1990.
52. Curran S and Murray GI: Matrix metalloproteinases: molecular aspects of their roles in tumor invasion and metastasis. Eur J Cancer 36: 1621-1630, 2000.
53. Ohkoshi M and Oka T: Clinical experience with a protease inhibitor [N, N-dimethylcarbamoylmethyl 4-(4-guanidino-benzoyloxy)-phenylacetate] methanesulfate for prevention of recurrence of carcinoma of the mouth and in treatment of terminal carcinoma. J Max-Fac Surg 12: 148-152, 1984.
54. Coussens LM, Fingelton B and Matrissian LM: Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295: 2387-2392, 2002.
55. Matrisian LM, Sledge GW and Mohla S: Extracellular proteolysis and cancer: meeting summary and future directions. Cancer Res 63: 6105-6109, 2003.
56. Reiter LA, Mitchell PG, Martinelli GJ, Lopresti-Morrow LL, Yocum SA and Eskra JD: Phosphinic acid-based MMP-13 inhibitors that spare MMP-1 and MMP-3. Bioorg Medic Chem Lett 13: 2331-2336, 2003.
57. Krol J, Kopitz C, Kirschenhofer A, Schmitt M, Magdolen, Kruger A and Magdolen V: Inhibition of intraperitoneal tumor growth of human ovarian cancer cells by bi- and trifunctional inhibitors of tumor-associated proteolytic systems. Biol Chem 384: 1097-1102, 2003.
58. Overall CM and Lopez-Otin C: Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nature Rev Cancer 2: 657-672, 2002.
59. Bohe H, Bohe M, Lindstrom C and Ohlsson K: Immunohistochemical demonstration of pancreatic secretory trypsin inhibitor in normal and neoplastic colonic mucosa. J Clin Pathol 43: 910-904, 1990.
60. Koshikawa N, Hasegawa S, Nagashima Y, Mitsuhashi K, Tsubota Y, Miyata S, Miyagi Y, Yasumitsu H and Miyazaki K: Expression of trypsin by epithelial cells of various tissues, leukocytes, and neurons in human and mouse. Am J Pathol 153: 937-944, 1998.
61. Koivunen E, Huhtala M-L and Stenman U-H: Human ovarian tumor-associated trypsin. Its purification and characterization from mucinous cyst fluid and identification as an activator of pro-urokinase. J Biol Chem 264: 14095-14099, 1989.
62. Koivunen E, Saksela O, Itkonen O, Osman S, Huhtala M-L and Stenman U-H: Human colon carcinoma, fibrosarcoma and leukemia cell lines produce tumor-associated trypsinogen. Int J Cancer 47: 592-596, 1991.
63. Kawano N, Osawa H, Ito T, Nagashima Y, Hirahara F, Inayama Y, Nakatani Y, Kimura S, Kitajima H, Koshikawa N, Miyazaki K and Kitamura H: Expression of gelatinase A, tissue inhibitor of metalloproteinase-2, matrilysin, and trypsin(ogen) in lung neoplasms: an immunohistochemical study. Human Pathol 28: 613-622, 1997.
64. Ohta T, Shimizu K, Yi S, Takamura H, Amaya K, Kitagawa H, Kayahara M, Ninomiya I, Fushida S, Fujimura T, Nishimura G and Miwa K: Protease-activated receptor-2 expression and the role of trypsin in cell proliferation in human pancreatic cancers. Int J Oncol 23: 61-66, 2003.
65. Kato Y, Nagashima Y, Koshikawa N, Miyagi Y, Yasumitsu H and Miyazaki K: Production of trypsin by human gastric cancer cells correlates with their malignant phenotype. Eur J Cancer 34: 1117-1123, 1998.
66. Oyama K, Ohta T, Nishimura GI, Elnemr A, Yasui T, Fujimura T, Fushida S, Kitagawa H, Kayahara M, Terada T and Miwa K: Trypsinogen expression in colorectal cancers. Int J Mol Med 6: 543-548, 2000.
67. Sorsa T, Salo T, Koivunen E, Tyynela J, Konttinen YT, Bergmann U, Tuuttila A, Niemi E, Teronen O, Heikkila P, Tschesche H, Leinonen J, Osman S and Stenman U-H: Activation of type IV procollagenase by human tumor-associated trypsin-2. J Biol Chem 272: 21067-21074, 1997.
68. Nyberg P, Moilanen M, Paju A, Sarin A, Stenman U-H, Sorsa T and Salo T: MMP-9 activation by tumor trypsin-2 enhances in vivo invasion of human tongue carcinoma cells. J Dent Res 81: 831-835, 2002.
69. Lukkonen A, Sorsa T, Salo T, Tervahartiala T, Koivunen E, Golub L, Simon S and Stenman U-H: Down-regulation of trypsinogen-2 expression by chemically modified tetracyklines: association with reduced cancer cell migration. Int J Cancer 86: 577-581, 2000.
70. Colomb E and Figarella C: Comparative studies on the mechanism of activation of the two human trypsinogens. Biochim Biophys Acta 571: 343-351, 1979.
71. Ohta T, Tajima H, Fushida, S, Kitagawa H, Kayahara M, Nagakawa T, Miwa K, Yamamoto M, Numata M, Nakamura Y, Kitamura Y and Terada T: Cationic trypsinogen produced by human pancreatic ductal cancer has the characteristics of spontaneous activation and gelatinolytic activity in the presence of proton. Int J Mol Med 1: 689-692, 1998.
72. Kobayashi H, Mobuhiko N, Sugimura M, Shinohara H, Ohi H and Terao T: Effect of membrane-associated cathepsin B on their activation of receptor-bound pro-urokinase and subsequent invasion of reconstituted basement membranes. Biochim Biophys Acta 1178: 55-62, 1993.
73. Figarella C, Miszczuk-Jamska B and Barrett AJ: Possible lysosomal activation of pancreatic zymogens. Activation of both human trypsinogen by cathepsin B and spontaneous acid activation of human trypsinogen 1. Biol Chem Hoppe-Seyler 369: 293-298, 1988.
74. Macfarlane SR, Scatter MJ, Kanke T, Hunter GD and Plevin R: Proteinase-activated receptors. Pharmacol Rev 53: 245-282, 2001.
75. Ichinose A, Fujikawa K and Suyama T: The Activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem 261: 3486-3489, 1986.
76. Campbell PG, Wines K, Yanosick TB and Novak JF: Binding and activation of plasminogen on the surface of osteosarcoma cells. J Cell Physiol 159: 1-10, 1994.
77. Yamashita K, Mimori K, Inoue H, Mori M and Sidransky D: A tumor-suppressive role for trypsin in human cancer progression. Cancer Res 63: 6575-6587, 2003.
78. Terada T, Ohta T, Minato H and Nakamura Y: Expression of pancreatic tryspinogen/trypsin and cathepsin B in human cholangiocarcinomas and hepatocellular carcinomas. Hum Pathol 26: 746-752, 1995.
79. Zutter MM and Santoro SA: The ups and downs of a2b1-integrin expression: contributions to epithelial cell differentiation and the malignant phenotype. In: Leukocyte Integrins in the Immune System and Malignant Disease (Holzmann B and Wagner H, eds). Berlin, Springer, pp. 167-185, 1998.
80. Polak-Charcon S, Shoham J and Ben-Shaul Y: Junction formation in trypsinized cells of human adenocarcinoma cell line. Exptl Cell Res 116: 1-13, 1978.
81. Kantak SS and Kramer RH: E-cadherin regulates anchorage-independent growth and survival in oral squamous cell carcinoma cells. J Biol Chem 273: 16953-16961, 1998.
82. Edwards JG and Campbell JA: The aggregation of trypsinized BHK21 cells. J Cell Sci 8: 53-71, 1971.
83. Edwards JG, Campbell JA, Robson RT and Vicker MG: Trypsinized BHK21 cells aggregate in the presence of metabolic inhibitors and in the absence of divalent cations. J Cell Sci 19: 653-667, 1975.
84. Chun MH: Plasmin induces the formation of multicellular spheroids of breast cancer cells. Cancer Lett 117: 51-56, 1997.
85. Chun MH: Serum signaling factors and spheroids. Crit Rev Oncol/Hematol 36: 89-98, 2000.
86. Small JV, Stradal T, Vignal E and Rottner K: The lamellipodium: where motility begins. Trends Cell Biol 12: 112-120, 2002.
87. Nobes CD and Hall A: Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell 81: 53-62, 1995.
88. Ehrlich JS, Hansen MDH and Nelson WJ: Spatio-temporal regulation of Rac1 localization and lamellipodia dynamics during epithelial cell-cell adhesion. Develop Cell 3: 259-270, 2002.
89. Fukata M, Nakagawa M and Kaibuchi K: Roles of Rho-family GTPases in cell polarization and directional migration. Curr Opin Cell Biol 15: 590-597, 2003.
90. Asgeirsson KS, Olafsdottir K, Jonasson JG and Ogmundsdottir HM: The effects of IL-6 on cell adhesion and e-cadherin expression in breast cancer. Cytokine 10: 720-728, 1998.
91. Shiras A, Bhosale A, Patekar A, Shepal V and Shastry P: Differential expression of CD44(S) and variant isoforms v3, v10 in three-dimensional cultures of mouse melanoma cell lines. Clin Exp Metastasis 19: 445-455, 2002.
92. Sun B, Ma H and Firtel RA: Dictyostelium stress-activated protein kinase alpha, a novel stress-activated mitogen-activated protein kinase-like kinase, is important for the proper regulation of the cytoskeleton. Mol Biol Cell 14: 4526-4540 2003.
93. Costerton W, Veeh R, Shirtliff M, Pasmore M, Post C and Ehrlich G: The application of biofilm science to the study and control of chronic bacterial infections. J Clin Invest 112: 1466-1477, 2003.
94. Cullen KJ, Yee D, Sly WS, Perdue J, Hampton B, Lippman ME and Rosen N: Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res 50: 48-53, 1990.
95. Rong H, Botenberg T, Maubach J, Stove C, Depypere H, Van Slambrouck S, Serreyn R, De Keukeleire D, Mareel M and Bracke M: 8-Prenylnaringenin, the phytoestrogen in hops and beer, upregulates the function of the E-cadherin/catenin complex in human mammary carcinoma cells. Eur J Cell Biol 80: 580-585, 2001.
96. Bates RC, Buret A, van Helden DF, Horton MA and Burns GF: Apoptosis induced by inhibition of intercellular contact. J Cell Biol 125: 403-415, 1994.
97. Bates RC, Edwards NS and Yates JD: Spheroids and cell survival. Crit Rev Oncol/Hematol 36: 61-74, 2000.
98. Desoize B and Jardillier J-C: Multicellular resistance: a paradigm for clinical resistance? Crit Rev Oncol/Hematol 36: 193-207, 2000.
99. Taback B, Chan AD, Kuo CT, Bostick PJ, Wang H-J, Giuliano AE and Hoon SB: Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay, correlation with clinical stage of disease. Cancer Res 61: 8845-8850, 2001.
100. Saurin J-C, Rouault J-P, Abello J, Berger F, Remy L and Chayvialle JA: High gastrin releasing peptide receptor mRNA level is related to tumour dedifferentiation and lymphatic vessel invasion in human colon cancer. Eur J Cancer 35: 125-132, 1999.
101. Luzzi KJ, MacDonald IC, Schmidt EE, Kerkvliet N, Morris VL, Chambers AF and Groom AC: Multistep nature of metastatic inefficiency. Dormancy of solitary cells after successful extravasation and limited survival of early micrometastasis. Am J Pathol 153: 865-873, 1998.
102. Condeelis J and Segall JE: Intravital imaging of cell movement in tumours. Nature Rev Cancer 3: 921-930, 2003.
103. Hasebe T, Sasaki S, Imoto S and Ochiai A: Histological characteristics of tumors in blood vessels play an important role in tumor progression of invasive ductal carcinoma of the breast. Cancer Sci 94: 158-165, 2003.
104. Croix B, Rak JW, Kapitain S, Sheehan C, Graham CH and Kerbel RS: Reversal by hyaluronidase of adhesion dependent multicellular drug resistance in mammary carcinoma cell. J Natl Cancer Inst 88: 1285-1296, 1996.
105. Al-Mehdi AB, Tozawa K, Fisher AB, Shientag L, Lee A and Muschel RJ: Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nature Med 6: 100-102, 2000.
106. Frisch SM and Francis H: Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 124: 619-626, 1994.
107. Stepanian LI and Vakhtin IB: Selection for affinity to lung tissue in cell populations of experimental neoplasms. (Otbor na affinitet k legochnoi tkani v kletochnykh populiatsiiakh eksperimetalnykh opukholei). Tsitologiia 22: 198-204, 1980.
108. Wald M, Olejar T, Pouckova P and Zadinova M: Proteinases reduce metastatic dissemination and increase survival time in C57B16 mice with the Lewis lung carcinoma. Life Sci 63: 237-243, 1998.
109. Wald M, Zavadova E, Pouckova P, Zadinova M and Boubelik M: Polyenzyme preparation Wobe-Mugos inhibits growth of solid tumors and development of experimental metastases in mice. Life Sci 62: 43-48, 1998.
110. Wald M, Olejar T, Sebkova V, Zadinova M, Boubelik M and Pouckova P: Mixture of trypsin, chymotrypsin and papain reduces formation of metastases and extends survival time of C57B16 mice with syngeneic melanoma B16. Cancer Chemother Pharmacol 47(Suppl.): S16-S22, 2001.
111. Beard J: The action of trypsin upon the living cells of Jensen's mouse-tumour. Br Med J 1: 140-141, 1906.
112. Beard J: Trypsin and amylopsin in cancer. Med Record 69: 1020, 1906.
113. von Leyden E and Bergell P: Ueber die therapeutische Verwendung des trypsin (Pankreatin) bei Karzinom. Zeitschrift fur Klinische Medizin 61: 360-364, 1907.
114. Novak JF and Trnka F: Proenzyme treatment of cancer. Anticancer Res 24: 3582, 2004.
115. Wen W, Moses MA, Wiederschain D, Arbiser JL and Folkman J: The generation of endostatin is mediated by elastase. Cancer Res 59: 6052-6056, 1999.
116. Felbor U, Dreier L, Bryant RA, Ploegh HL, Olsen BR and Mothes W: Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J 19: 1187-1194, 2000.
117. Gately SP, Stack MS, Cundiff DL, Grella D, Castellino FJ, Enghild J, Kwaan HC, Lee F, Kramer RA, Volpert O, Bouck N and Soff GA: The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. PNAS 94: 10868-10872, 1997.
118. Cao R, Wu H-L, Veitonmaki N, Lindeen P, Farnebo J, Shi G-Y and Cao Y: Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis. Proc Natl Acad Sci USA 96: 5728-5733, 1999.
119. Dong Z, Kumar R, Yang X and Fidler IJ: Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 88: 801-810, 1997.
120. Hakansson HO, Borgstrom A and Ohlsson K: Porcine pancreatic cationic pro-elastase. Studies on the activation, turnover and interaction with plasma proteinase inhibitors. Biol Chem Hoppe Seyler 372: 465-472, 1991.
121. Standker L, Schrader M, Kanse SM, Jurgens M, Forssmann WG and Preissner KT: Isolation and characterization of the circulating form of human endostatin. FEBS Lett 420: 129-133, 1997.
122. Cao Y: Endogenous angiogenesis inhibitors: angiostatin, endostatin, and other proteolytic fragments. Progr Mol Subcell Biol 20: 161-176, 1998
123. Roberts W: On the estimation of the amylolytic and proteolytic activity of pancreatic extracts. Proc Royal Soc London 32: 145-161, 1881.
124. Sarrias MR, Gronlund J, Padilla O, Madsen J, Holmskov U and Lozano F: The scavenger receptor cysteine-rich (SRCR) domain: an ancient and highly conserved protein module of the innate immune system. Crit Rev Immunol 24: 1-38, 2004.
125. Antonucci F, Vezzadini P, Adorati M, Bonora G, Messa P, Montanaro D and Mioni G: Serum trypsin-like immunoreactivity and secondary hyperparathyroidism in renal failure. Scand J Gastroenterol 15(Suppl. 62): 53-57, 1980.
126. Janeway CA Jr: How the immune system works to protect the host from infection: a personal view. Proc Natl Acad Sci USA 98: 7461-7468, 2001.
127. Brandtzaeg P, Baekkevold ES, Farstad IN, Jahnsen FL, Johansen F-E, Nilsen EM and Yamanaka T: Regional specialization in the mucosal immune system: what happens in the microcompartments? Immunol Today 20: 141-151, 1999.
128. Cleland JL and Langer R: Formulation and delivery of proteins and peptides: design and development strategies. In: Formulation and Delivery of Proteins and Peptides. (Cleland JL and Langer R, eds). Washington, DC, American Chemical Society, pp. 1-21, 1994.
129. Boehm T, Folkman J, Browder T and O'Reilly MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390: 404-407, 1997.